More States Move to Drop GLP-1 Weight Loss Drug Coverage from Medicaid as Costs Strain Budgets Nationwide
Why It Matters
For millions of low-income Americans enrolled in Medicaid, access to expensive GLP-1 weight loss medications like Ozempic may soon disappear — not because of a federal mandate, but because state governments are struggling to absorb the rapidly rising cost of covering these drugs. The trend raises serious questions about how states balance taxpayer obligations with expanding government health benefit programs.
The pressure on state Medicaid budgets is intensifying, and several states are now reconsidering whether weight loss drugs represent an appropriate or sustainable use of limited public funds.
What Happened
Massachusetts and Rhode Island are the latest states considering dropping GLP-1 drug coverage for obesity treatment from their Medicaid programs, according to reporting by Stateline. Both governors have proposed budget plans that would eliminate weight loss coverage for the medications, though coverage for diabetes and other conditions would remain in place in Massachusetts.
The Massachusetts governor’s proposed fiscal year 2028 budget would end funding for the state’s Medicaid program, known as MassHealth, to cover GLP-1 medications solely for weight loss purposes. The state legislature is still debating that budget. Rhode Island’s governor has similarly proposed removing GLP-1 obesity coverage from the state’s Medicaid program.
The proposals continue a national trend. California, New Hampshire, Pennsylvania, and South Carolina have already eliminated Medicaid coverage of the drugs for weight loss, citing budget strain. North Carolina briefly dropped coverage in October before reinstating it in mid-December.
By the Numbers
- Thirteen state Medicaid programs currently cover GLP-1 drugs for obesity treatment in 2026, down from 16 the prior year.
- Gross Medicaid spending on GLP-1 prescriptions — for both diabetes and weight loss — surged from approximately $1 billion in 2019 to nearly $9 billion in 2024, according to health policy research group KFF.
- Michigan restricted eligibility to morbidly obese patients rather than those who are simply overweight or obese, a move estimated to save the state approximately $240 million.
- Novo Nordisk, one of the largest GLP-1 manufacturers, announced in February that it would reduce list prices to $675 per month beginning in 2027.
- Nearly 40% of adults and a quarter of children enrolled in Medicaid have obesity, according to KFF.
Zoom Out
The debate over GLP-1 drugs is part of a broader national reckoning over how far government health programs should extend in covering treatments that blur the line between medical necessity and lifestyle management. States that have expanded Medicaid benefits in recent years are now discovering that the long-term cost of those expansions is unsustainable — a lesson fiscal conservatives have long warned about.
The medications have generally been unaffordable for uninsured individuals, meaning Medicaid coverage represented the primary access point for low-income patients. That access is now narrowing as state budget pressures mount. Louisiana is taking a different approach, with lawmakers debating whether to allow GLP-1 coverage for Medicaid enrollees who have obesity alongside another chronic condition — such as prediabetes, hypertension, or cardiovascular disease — effectively tightening eligibility rather than eliminating the benefit outright.
States including Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, Tennessee, Utah, Virginia, and Wisconsin currently cover the drugs for obesity treatment, though some have added restrictions on who qualifies.
The issue intersects with ongoing national healthcare cost debates. A related court battle over medication access has drawn attention as well — an appeals court recently blocked remote access to abortion medication nationwide, reflecting broader legal and policy tensions surrounding prescription drug access through government and insurance channels.
What’s Next
Massachusetts lawmakers will continue debating the state’s fiscal year 2028 budget, with the GLP-1 coverage question remaining unresolved. Rhode Island’s proposal will similarly move through its budget process in the coming months.
Nationally, the trajectory appears clear: as government spending on these drugs continues to climb, more states are likely to reassess coverage eligibility, impose restrictions, or eliminate weight loss coverage altogether while retaining coverage for diabetes treatment. Whether Novo Nordisk’s planned 2027 price reduction will be enough to reverse that trend remains to be seen.
About the Author
